AbbVie v. Zenara Pharma: Elagolix ANDA Infringement Resolved in 137 Days
AbbVie asserted two patents covering its ORILISSA elagolix sodium tablets against Zenara Pharma’s ANDA No. 217760 in the Delaware District Court. The case resolved in just 137 days via a stipulated consent order that found infringement and imposed a permanent injunction barring Zenara’s generic entry for the life of both patents.
Consent Injunction Locks Out Generic Elagolix for Patent Life
On 5 February 2024, AbbVie, Inc. filed suit in the Delaware District Court against Zenara Pharma Private Ltd. and Biophore India Pharmaceuticals Private Ltd., asserting that the filing of ANDA No. 217760 — covering generic elagolix sodium oral tablets at 150 mg and 200 mg base equivalents — constituted an act of infringement under 35 U.S.C. § 271(e)(2)(A) with respect to US11690845B2 and US11690854B2, the two patents protecting AbbVie’s branded ORILISSA product.
The action resolved on 21 June 2024 through a stipulated consent order signed by Judge Jennifer L. Hall. The order formally adjudicated that ANDA filing was an act of infringement of both patents and entered a permanent injunction prohibiting Zenara from manufacturing, selling, or importing the ANDA products in the United States for the life of either patent, including any extensions or pediatric exclusivities. All remaining claims, counterclaims, and defenses were dismissed without prejudice, preserving each party’s ability to litigate future disputes concerning the same patents but different products.
Resolution in 137 days is notably swift for Hatch-Waxman ANDA litigation, which typically benefits from a 30-month stay and often extends to trial. The speed and structure of the consent order suggests Zenara concluded it could not overcome both patents and negotiated an exit that preserves a Paragraph IV certification and leaves future product configurations open. The absence of a license or market-entry date indicates no settlement royalty or commercial concession visible from the public record.
Filing to Dismissed without Prejudice in 137 days
137 days — well under the typical 2–3 year ANDA litigation cycle in Delaware
Stipulated consent order: infringement found, injunction entered, claims dismissed without prejudice
Stipulated infringement finding under 35 U.S.C. § 271(e)(2)(A)
Under the Hatch-Waxman Act, the filing of an ANDA with a Paragraph IV certification is itself a statutory act of infringement under § 271(e)(2)(A). Here, both parties stipulated to that finding, allowing the court to enter a consent judgment without a merits trial. Remaining claims were dismissed without prejudice — meaning no res judicata bar on future product-specific disputes.
Consent judgment — no trial requiredDismissal preserves future claims — but only for different products
A dismissal without prejudice means neither party is barred from re-litigating claims in the future. Critically, the order expressly carves out only ANDA No. 217760’s specific 150 mg and 200 mg elagolix sodium tablets. Any different product or formulation covered by the same patents remains fair game. Zenara also retains its Paragraph IV certification, consistent with a strategy to continue challenging patent validity or non-infringement for other products.
Future product claims remain openAbbVie secures full-life injunction protecting ORILISSA market exclusivity
AbbVie obtained everything a patent holder typically seeks in Hatch-Waxman litigation: a court-ordered finding of infringement, a permanent injunction covering the full patent term including extensions and pediatric exclusivities, and a waiver of Zenara’s appeal rights. ORILISSA’s commercial position is protected against this specific ANDA for as long as either patent remains in force.
Full-term injunction grantedZenara exits this ANDA battle but retains strategic optionality
Zenara waived appeal rights on the consent order and is enjoined from launching the specific ANDA products. However, by preserving a Paragraph IV certification and securing a without-prejudice dismissal on all other claims, Zenara maintains the ability to pursue patent challenges or launch different elagolix formulations in future proceedings. The absence of a license or entry date suggests no agreed commercial pathway for this ANDA.
Paragraph IV cert retainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of US11690845B2 and US11690854B2 (ORILISSA)Search in Eureka ↗ |
| Defendant | Zenara Pharma Private, Ltd. | Company | Indian generic pharmaceutical developer; ANDA applicant for elagolix sodium tabletsSearch in Eureka ↗ |
| Co-Defendant | Biophore India Pharmaceuticals Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order’s operative language is precise: it formally adjudicates ANDA filing as an act of infringement under § 271(e)(2)(A) — a statutory infringement finding, not merely a contractual concession. The permanent injunction covering the full patent life, including extensions and pediatric exclusivities, provides AbbVie with the broadest available exclusivity protection. Zenara’s express waiver of appeal rights eliminates any uncertainty from post-order challenge. The without-prejudice dismissal of remaining claims is a deliberate structural choice, not a concession — it keeps future product disputes alive and avoids any admission on validity or non-infringement defenses that could have wider Orange Book implications.
US11690845B2 & US11690854B2 — Elagolix Sodium Oral Tablet Formulations
US11690845B2 and US11690854B2 protect formulations of elagolix sodium, a GnRH receptor antagonist marketed by AbbVie as ORILISSA for the management of endometriosis-associated pain and, at higher doses, uterine fibroids. Both patents issued from applications filed in the early 2020s and cover the specific oral solid dosage forms — including 150 mg and 200 mg base equivalent tablet strengths — that are the subject of Zenara’s ANDA. Their inclusion on the FDA Orange Book requires any Paragraph IV ANDA filer to certify and litigate, triggering the § 271(e)(2)(A) infringement mechanism invoked here.
Elagolix is a high-value women’s health asset for AbbVie, and protecting its formulation patents is commercially critical given the drug’s position in a growing GnRH antagonist market that also includes relugolix and linzagolix. The two patents, covering specific tablet formulations rather than the active molecule itself, represent a second-generation protection strategy designed to extend exclusivity beyond any compound patent expiry. Generic challengers must either design around both formulation patents or invalidate them — a dual hurdle that likely drove Zenara’s decision to stipulate rather than litigate.
Should your team run an FTO against US11690845B2 and US11690854B2?
Any pharmaceutical company, CDMO, or API manufacturer developing elagolix sodium oral dosage forms — or formulation technologies that could overlap with GnRH antagonist tablet compositions — should conduct a freedom-to-operate analysis against both patents. The consent order confirms that both patents are actively enforced and that AbbVie has already secured a permanent injunction against one ANDA applicant. The without-prejudice dismissal of Zenara’s invalidity and non-infringement defenses means those defences have never been tested on the merits, leaving the patents presumptively valid.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11690845B2 and US11690854B2 against your proposed formulation, identify prior art that may support IPR petitions, and surface related AbbVie filings in the same patent family. Eureka also tracks Orange Book listings and PTAB petitions in real time, enabling R&D and IP teams to monitor litigation risk as the elagolix exclusivity landscape evolves.
Run a freedom-to-operate analysis on US11690845B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA Cases Involving GnRH Antagonist Formulation Patents
Explore comparable ANDA infringement actions in the Delaware District Court involving formulation patents for small-molecule women’s health and GnRH antagonist drugs.
What this case signals for the Hatch-Waxman pharmaceutical IP landscape
AbbVie’s swift consent order outcome illustrates how branded pharma can efficiently lock out generic competition without full Hatch-Waxman litigation.
Consent orders are a fast, low-cost tool for blocking ANDA-based generic entry
This case resolved in 137 days — a fraction of the typical ANDA litigation timeline. When a generic applicant cannot credibly challenge both asserted patents, branded holders can often convert early negotiations into a stipulated infringement finding and permanent injunction, preserving exclusivity without the cost and uncertainty of trial.
Without-prejudice terms preserve litigation risk for both sides beyond this ANDA
The express carve-out for non-ANDA-217760 products means AbbVie and Zenara could face each other again if Zenara files a new ANDA or NDA for a different elagolix formulation. Companies monitoring ORILISSA’s IP estate should track subsequent Zenara filings against these same patents.
AbbVie v Zenara — key questions answered
Judge Jennifer L. Hall entered a stipulated consent order on 21 June 2024 finding that Zenara’s filing of ANDA No. 217760 was an act of infringement of US11690845B2 and US11690854B2 under 35 U.S.C. § 271(e)(2)(A), and permanently enjoining Zenara from launching the generic elagolix sodium tablets for the life of both patents including any extensions and pediatric exclusivities. All other claims were dismissed without prejudice.
AbbVie asserted US11690845B2 (application US17/004817) and US11690854B2 (application US17/047871), both covering elagolix sodium oral tablet formulations at 150 mg and 200 mg base equivalent strengths marketed as ORILISSA. Both patents are listed in the FDA Orange Book and triggered the Hatch-Waxman § 271(e)(2)(A) infringement mechanism upon Zenara’s ANDA filing.
The without-prejudice dismissal of remaining claims, counterclaims, and defenses means neither party is barred by res judicata or claim preclusion from re-litigating those issues in a future action. The order expressly carves out only the specific ANDA No. 217760 products, preserving both parties’ rights to litigate claims related to the same patents but involving different elagolix products or formulations.
Yes, subject to limits. Zenara retains its Paragraph IV certification against US11690845B2 and US11690854B2 under the consent order, which is consistent with future IPR petitions at the USPTO or new ANDA filings covering different elagolix formulations. However, Zenara expressly waived the right to appeal or seek relief from the consent order itself, and is permanently enjoined from launching the specific ANDA No. 217760 products.
The case closed in 137 days, well under the typical 2–3 year Hatch-Waxman litigation cycle. This speed suggests Zenara assessed it could not successfully challenge both asserted patents and negotiated a structured exit via consent order rather than proceeding to trial. The absence of a license, entry date, or financial terms in the public record is consistent with a straight injunction outcome rather than a commercial settlement with market-access provisions.
PatSnap Eureka searches patents and litigation data to answer instantly.